the firm is confident its new drug pipeline will deliver profits despite the failure of an obesity drug.mr garnier said the company had absorbed over 1.5bn of lost sales to generics but still managing to grow the business.however, the firm discontinued development of an experimental treatment for obesity, known as '771, after disappointing clinical trial results.glaxo is relying on new treatments for conditions such as cancer, diabetes, depression, hiv aids and allergies to lift the pace of sales growth after several disappointing years.